Proteomics in Cell Biology and Disease Mechanisms Feb 28, 2018 20180228 Mar 2, 2018 UK In association with EMBL, the second Proteomics in Cell Biology and Disease Mechanisms conference will take place in Cambridge. This conference will focus on novel proteomics approaches to study long-standing questions in cell biology and disease mechanisms. /content/dam/pmiscience/default-fallback-thumbnails/conference/pmi-science-product-laboratory1-fallback.jpg

      Proteomics in Cell Biology and Disease Mechanisms

      Date
      Feb 28, 2018 - Mar 2, 2018
      Location
      UK
      In association with EMBL, the second Proteomics in Cell Biology and Disease Mechanisms conference will take place in Cambridge. This conference will focus on novel proteomics approaches to study long-standing questions in cell biology and disease mechanisms.

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts to develop and assess products that have the potential to reduce individual risk and population harm associated with tobacco use. This site is for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not for advertising or marketing. It is not intended for use by consumers.

      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. Our RRPs are smoke-free products that produce an aerosol that contains far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.